ArticleScientific reports2021
Common osteoporosis drug associated with increased rates of depression and anxiety.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- The anti-osteoporotic effect of puerarin on the femoral bone in rat models of osteoporosis: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Effects of osthole on osteoporotic rats: a systematic review and meta-analysis.Pharmaceutical biology · 2022Pooled it
- Therapeutic strategy for exosome-based bone regeneration to osteoporosis: Challenges and potential solutions.Journal of advanced research · 2026Review
- The Bone-Brain Axis: Novel Insights into the Bidirectional Crosstalk in Depression and Osteoporosis.Biomolecules · 2026Review
- Comprehensive analysis of sparsentan-related adverse events: latest insights from VigiAccess and FAERS.Journal of nephrology · 2025Article
- An Analysis of Primary Hyperparathyroidism in Association with Depression or Anxiety.Diseases (Basel, Switzerland) · 2025Review
- A Pharmacovigilance Study from 2004 to 2024 Utilizing the FDA Adverse Event Reporting System (FAERS) Examines Ischemic Adverse Events Linked to Triptan Use in Migraine Therapy.Journal of pain research · 2025Article
- Association between depression and osteoporosis in a population of cancer survivors: results from the NHANES 2005-2020.Frontiers in medicine · 2025Article
- Effect of RANKL on Lower Depressive Symptoms In Hemodialysis Patients.Calcified tissue international · 2024Article
- Article
- Repurposing Ketamine in the Therapy of Depression and Depression-Related Disorders: Recent Advances and Future Potential.Aging and disease · 2024Review
- Catgut embedding in acupoints combined with repetitive transcranial magnetic stimulation for the treatment of postmenopausal osteoporosis: study protocol for a randomized clinical trial.Frontiers in neurology · 2024Article
- Association of a history of gestational diabetes mellitus with osteoporosis, bone mineral density, and trabecular bone score in postmenopausal women.Diabetology & metabolic syndrome · 2023Article
- Anti-TNF-α therapy induced psoriasis in rheumatoid arthritis patients according to FDA postmarketing surveillance data.Scientific reports · 2023Article
- Daytime administration of melatonin has better protective effects on bone loss in ovariectomized rats.Journal of orthopaedic surgery and research · 2023Article
- Peptide Engraftment on PEGylated Nanoliposomes for Bone Specific Delivery of PTH (1-34) in Osteoporosis.Pharmaceutics · 2023Article
- Article
- Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system.Frontiers in psychiatry · 2023Article
- Interrelations between clinical-psychological features and bone mineral density changes in post-menopausal women undergoing anti-osteoporotic treatment: a two-year follow-up.Frontiers in endocrinology · 2023Article
- Emotional distress and multimorbidity patterns in Chinese Han patients with osteoporosis: a network analysis.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Osteoporosis affects over 10 million Americans over 50. Bisphosphonate therapy, mainly alendronate, is amongst the most prescribed treatments for the disease. The use of alendronate and other bisphosphonates has been associated with depressive symptoms in recent case reports. In this study we quantified this association by analyzing over 100,000 adverse events reports from the Food and Drug Administration Adverse Events Reporting System (FAERS) and the World Health Organization's (WHO) global database for adverse drug reactions, ADRs, VigiAccess. We found that alendronate therapy is significantly associated with depression and anxiety when compared to other first-line osteoporosis treatments. The reported risk of depressive ADRs was found to be over 14-fold greater in patients taking alendronate under the age of 65 and over fourfold greater for patients over 65 compared to the control. Several hypotheses concerning the molecular mechanism of the observed association of alendronate and depressive symptoms were discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.